Navigation Links
Plasma protein appears to be associated with development and severity of Alzheimer's disease
Date:7/5/2010

Higher concentrations of clusterin, a protein in the blood plasma, appears to be associated with the development, severity and progression of Alzheimer's disease, according to a report in the June issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

Individuals with Alzheimer's disease display several findings in their blood and cerebrospinal fluid that may reflect neuropathological changes, according to background information in the article. For instance, in cerebrospinal fluid, individuals with Alzheimer's disease have lower levels of amyloid-beta peptides and higher levels of total and phosphorylated tau concentration, which reflect the formation of hallmark plaques and tangles in the brain. Similarly, numerous articles have suggested that levels of certain metabolites and proteins in the plasma might represent responses to brain changes in Alzheimer's disease, but none have been replicated.

Madhav Thambisetty, M.D., Ph.D., of Institute of Psychiatry, King's College London, and colleagues used a combined proteomic and neuro-imaging approach to identify plasma proteins associated with Alzheimer's disease pathology. Participants in two studiessome with Alzheimer's disease, some with its precursor mild cognitive impairment and some with no dementiaunderwent standardized clinical assessments and brain imaging scans. Their blood plasma was then assessed for proteins that may be associated with Alzheimer's disease.

Based on findings of two "discovery phase" studies in 95 patients, one protein, clusterin, appeared to be associated with atrophy of the hippocampal region of the brain and with rapid progression of cognitive decline. The researchers then studied clusterin levels in all 689 participants (including 464 with Alzheimer's disease) and found an association between higher plasma levels of the protein and severity of disease, rapid clinical progression and atrophy in the brain area known as the entorhinal cortex, which plays a role in memory. In addition, increased clusterin levels in the plasma were associated with having more amyloid-betawhich forms the brain plaques associated with Alzheimer's diseasein the brain's medial temporal lobe.

According to the authors, "previous studies suggest that clusterin belongs to a family of extracellular chaperones," proteins that regulate the formation and removal of amyloid. "Although these findings do not support the clinical utility of plasma clusterin concentration as a stand-alone biomarker for Alzheimer's disease, they reveal a robust peripheral signature of this amyloid chaperone protein that is responsive to key features of disease pathology."

"Our findings clearly implicate clusterin, but there may well be other proteins in plasma related to the disease process, and indeed our previous studies and those of others suggest this is the case," they conclude. "These results may have wider implications for the identification of other amyloid chaperone proteins in plasma, both as putative Alzheimer's disease biomarkers as well as drug targets of disease-modifying treatments."


'/>"/>

Contact: Louise Pratt
louise.a.pratt@kcl.ac.uk
44-207-848-5378
JAMA and Archives Journals
Source:Eurekalert

Related medicine news :

1. Painless Plasma Jets Instead of Dental Drill?
2. Platelet-rich Plasma Enhances Bone and Tissue Growth for Dental Implants
3. For Achilles Overuse, Plasma Injections Look No Better Than Placebo
4. Restrictions on female plasma may not be warranted
5. Restrictions on Plasma From Female Donors May Need Revisiting
6. Inappropriate uses of frozen plasma
7. New York Sports Medicine Offers Platelet Rich Plasma Therapy For Treatment of Injury
8. After Teeth Are Pulled, Platelet-Rich Plasma May Speed Healing
9. Scientists ID a protein that splices and dices genes
10. 3 brain diseases linked by toxic form of same neural protein
11. Protein Levels in Urine Help Predict Kidney Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... ... clinician-based audience, will be participating in Rare Disease Day events, hosted by the ... addition, Rare Disease Report, a website, weekly e-newsletter and quarterly publication, will be ...
(Date:2/23/2017)... Fair Lawn, NJ (PRWEB) , ... February 23, ... ... specializing in thought leadership , media relations, content marketing, social media ... Vermont. With several clients already in the state and in nearby New Hampshire, ...
(Date:2/23/2017)... ... February 23, 2017 , ... Pink Pig Publishing LLC ... converge and explore the world from different perspectives. By providing a place for ... gain understanding, increase empathy, and find greater happiness. , "Our approach to ...
(Date:2/23/2017)... Lincoln, RI (PRWEB) , ... February 23, 2017 ... ... announced today a new partnership with the Rhode Island Consortium for Autism Research ... provide an opportunity for children with autism spectrum disorder (ASD) to see films ...
(Date:2/23/2017)... ... February 23, 2017 , ... Curemark, LLC announced today ... efficacy of CM-AT in children aged 3-8 with Autism, is now enrolling at three ... enrolling children across the United States. , “There are currently no approved drugs ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , Feb 23, 2017 Research and Markets has ... - 2016" report to their offering. ... The latest research Menopause Drugs Price Analysis and Strategies ... market. The research answers the following questions: ... attributes? How are they positioned in the Global Menopause market? ...
(Date:2/23/2017)... CITY, Calif. , Feb. 23, 2017 /PRNewswire/ ... pharmaceutical company focused on the development and commercialization ... acute pain, announced that it will release fourth ... on Thursday, March 2nd, 2017. AcelRx management will ... Eastern Time (1:30 p.m. Pacific Time) on March ...
(Date:2/23/2017)... Research and Markets has announced the addition of the "Global ... report to their offering. ... The Global Endoscopy Market is poised to grow at ... approximately $47.6 billion by 2025. This industry report ... on global as well as regional levels presented in the research ...
Breaking Medicine Technology: